Maricel Apuli insider trades: BridgeBio Pharma (BBIO) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Maricel reports to the SEC
Open-market buys and sales
6 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 30, 2026 | BBIO | ↓ Sell | 2,000 | $72.85 | $146K | Direct | Nov 3, 2026 (4d) |
| Jul 30, 2026 | BBIO | ↓ Sell | 2,000 | $80.06 | $160K | Direct | Aug 3, 2026 (4d) |
| Feb 17, 2026 | BBIO | ↓ Sell | 510 | $74.31 | $38K | Direct | Feb 18, 2026 (1d) |
| Dec 8, 2025 | BBIO | ↓ Sell | 2,000 | $74.26 | $149K | Direct | Dec 10, 2025 (2d) |
| Aug 7, 2025 | BBIO | ↓ Sell | 1,000 | $45.44 | $45K | Direct | Aug 11, 2025 (4d) |
| May 2, 2025 | BBIO | ↓ Sell | 1,026 | $38.51 | $40K | Direct | May 6, 2025 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other BBIO insiders
Open-market trades in the last 12 months
About Maricel Apuli's insider trades
Maricel Apuli is Chief Accounting Officer at BridgeBio Pharma (BBIO). Since May 2, 2025, Maricel has reported no open-market purchases and 6 sales worth $577K on SEC Form 4. In the last 12 months: 4 sales ($492K).
Their filings also include shares withheld for taxes (7 filings), grants and awards (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BBIO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.